EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer

References

• Beh CW, Seow WY, Wang Y, et al. (2008). Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug. Biomacromolecules 10:41–8
   Web of Science ®Google Scholar
• Beija M, Salvayre R, Lauth-de Viguerie N, et al. (2012). Colloidal systems for drug delivery: from design to therapy. Trends Biotechnol 30:485–96
   PubMed Web of Science ®Google Scholar
• Brand TM, Iida M, Luthar N, et al. (2013). Nuclear EGFR as a molecular target in cancer. Radiother Oncol 108:370–7
   PubMed Web of Science ®Google Scholar
• Brannon-Peppas L, Blanchette JO. (2012). Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 64:206–12
   Web of Science ®Google Scholar
• Chougule A, Prabhash K, Noronha V, et al. (2013). Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity. PLoS One 8:e76164
   PubMed Web of Science ®Google Scholar
• Davis ME, Zuckerman JE, Choi CHJ, et al. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067–70
   PubMed Web of Science ®Google Scholar
• Du J, Sun Y, Shi QS, et al. (2012). Biodegradable nanoparticles of mPEG-PLGA-PLL triblock copolymers as novel non-viral vectors for improving siRNA delivery and gene silencing. Int J Mol Sci 13:516–33
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Cheng J, Teply BA, et al. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103:6315–20
   PubMed Web of Science ®Google Scholar
• Heo MB, Lim YT. (2014). Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells. Biomaterials 35:590–600
   PubMed Web of Science ®Google Scholar
• Jain RK, Stylianopoulos T. (2010). Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7:653–64
   PubMed Web of Science ®Google Scholar
• Koty PP, Zhang H, Levitt ML. (1999). Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer 23:115–27
   PubMed Web of Science ®Google Scholar
• Li HY, Hu J, Zhao S, et al. (2012). Comparative study of the effect of baicalin and its natural analogs on neurons with oxygen and glucose deprivation involving innate immune reaction of TLR2/TNFα. J Biomed Biotechnol 2012:Article ID 267890
   PubMedGoogle Scholar
• Liu P, Yu H, Sun Y, et al. (2012). A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery. Biomaterials 33:4403–12
   PubMed Web of Science ®Google Scholar
• Lwin Z, Riess JW, Gandara D. (2013). The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era. J Thorac Dis 5:S556–64
   PubMed Web of Science ®Google Scholar
• Molina JR, Yang P, Cassivi SD, et al. (2008). Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proc 83:584–94
   PubMed Web of Science ®Google Scholar
• Rathos MJ, Khanwalkar H, Joshi K, et al. (2013). Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells. BMC Cancer 13:29
   PubMed Web of Science ®Google Scholar
• Sartorius UA, Krammer PH. (2002). Upregulation of bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97:584–92
   PubMed Web of Science ®Google Scholar
• Sheng Q, Liu J. (2011). The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer 104:1241–5
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. (2012). Cancer statistics. Cancer J Clin 62:10–29
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. (2013). Cancer statistics, 2013. Cancer J Clin 63:11–30
   PubMed Web of Science ®Google Scholar
• Singhal SS, Wickramarachchi D, Singhal J, et al. (2006). Determinants of differential doxorubicin sensitivity between SCLC and NSCLC. FEBS Lett 580:2258–64
   PubMed Web of Science ®Google Scholar
• Sridhar SS, Seymour L, Shepherd FA. (2003). Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4:397–406
   PubMed Web of Science ®Google Scholar
• Stigliano C, Aryal S, de Tullio MD, et al. (2014). siRNA-chitosan complexes in poly(lactic-co-glycolic acid) nanoparticles for the silencing of aquaporin-1 in cancer cells. Mol Pharm 10:3186–94
   Web of Science ®Google Scholar
• Su WP, Cheng FY, Shieh DB, et al. (2012). PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomedicine 7:4269–83
   PubMed Web of Science ®Google Scholar
• Tseng CL, Wang TW, Dong GC, et al. (2007). Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 28:3996–4005
   PubMed Web of Science ®Google Scholar
• Wang JQ, Du ZW, Gao XF, et al. (2013a). [The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs]. Zhonghua Jie He Hu Xi Za Zhi 36:191–7
   PubMedGoogle Scholar
• Wang Y, Liu P, Qiu L, et al. (2013b). Toxicity and therapy of cisplatin-loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice. Biomaterials 34:4068–77
   PubMed Web of Science ®Google Scholar
• Wu DW, Wu TC, Wu JY, et al. (2013). Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression. Oncogene 33:4385–95
   PubMed Web of Science ®Google Scholar
• Yang J, Liu X, Bhalla K, et al. (1997). Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275:1129–32
   PubMed Web of Science ®Google Scholar
• Yin P, Wang Y, Qiu YY, et al. (2012). Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity. Int J Nanomedicine 7:3961–9
   PubMed Web of Science ®Google Scholar
• Zarogoulidis K, Zarogoulidis P, Darwiche K, et al. (2013). Treatment of non-small cell lung cancer (NSCLC). J. Thorac Dis 5:S389–96
   PubMed Web of Science ®Google Scholar
• Zhao P, Dai M, Chen W, et al. (2010). Cancer trends in China. Jpn J Clin Oncol 40:281–5
   PubMed Web of Science ®Google Scholar
• Ziegler A, Luedke GH, Fabbro D, et al. (1997). Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 89:1027–36
   PubMed Web of Science ®Google Scholar